Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | PEPD | P12955 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3151603 | 1.00 | CYP1A2 (0.38) | CYP1A2USP2ALDH1A1LMNATSHR | |
| SCHEMBL3686565 | 1.00 | CYP1A2 (0.38) | CYP1A2USP2ALDH1A1LMNATSHR | |
| SCHEMBL3152635 | 1.00 | CYP1A2 (0.38) | CYP1A2USP2ALDH1A1LMNATSHR | |
| SCHEMBL13450787 | 1.00 | CYP1A2 (0.38) | CYP1A2USP2ALDH1A1LMNATSHR | |
| SCHEMBL1924296 | 1.00 | CYP1A2 (0.38) | CYP1A2USP2ALDH1A1LMNATSHR | |
| SCHEMBL14547320 | 1.00 | CYP1A2 (0.38) | CYP1A2USP2ALDH1A1LMNATSHR | |
| SCHEMBL3156153 | 1.00 | CYP1A2 (0.38) | CYP1A2USP2ALDH1A1LMNATSHR | |
| SCHEMBL3147308 | 1.00 | CYP1A2 (0.38) | CYP1A2USP2ALDH1A1LMNATSHR | |
| SCHEMBL21622002 | 1.00 | CYP1A2 (0.38) | CYP1A2USP2ALDH1A1LMNATSHR | |
| SCHEMBL121350 | 1.00 | CYP1A2 (0.38) | CYP1A2USP2ALDH1A1LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020198261-A1 | Liquid pharmaceutical compositions | KULKARNI NEEMA M (US) | 2002-12-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198261-A1 | Liquid pharmaceutical compositions | GABRB2, GABRB1, GABRA6 | CYP1A2 1219/4885USP2 3682/4885ALDH1A1 932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.